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Precis: Breast cancer survival remained high from 2001 to 2009, but there were wide and 
persistent disparities in survival between black and white women. Reducing racial disparities in 
breast cancer survival remains a challenge that requires broad, coordinated efforts at the federal, 
state, and local levels.  
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ABSTRACT 
Background: Reducing breast cancer incidence and achieving equity in breast cancer outcomes 
remains a priority for public health practitioners, health care providers, policy makers and health 
advocates. Monitoring breast cancer survival can help evaluate the effectiveness of health 
services, quantify inequities in outcomes between states or population sub-groups, and inform 
efforts to improve the effectiveness of cancer management and treatment. 
Methods: We analyzed breast cancer survival using individual patient records from 37 statewide 
registries that participated in the CONCORD-2 study, covering approximately 80% of the US 
population. Women were diagnosed during 2001-2009 and followed up through December 31, 
2009.  We estimated age-standardized net survival at 1, 3 and 5 years after diagnosis, by state, 
race (white, black), stage at diagnosis, and calendar period (2001–2003 and 2004–2009).   
Results: Overall, 5-year breast cancer net survival is very high (88.2%). Survival remained 
remarkably high from 2001 to 2009. During 2001–2003, survival was 89.1% for white women 
and 76.9% for black women. During 2004–2009, survival was 89.6% for white women and 
78.4% for black women.  
Conclusion: Breast cancer survival was more than 10 percentage points lower for black women 
than for white women and this difference persisted over time. Reducing racial disparities in 
survival remains a challenge that requires broad, coordinated efforts at the federal, state, and 
local levels. Monitoring trends in breast cancer survival can highlight populations in need of 
improved cancer management and treatment. 
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INTRODUCTION 
The burden of breast cancer has been a persistent concern among public health practitioners, 
health care providers, policy makers, and health advocates. Worldwide, breast cancer is the 
second most common cancer and the fifth leading cause of cancer deaths among women.1 In the 
United States, breast cancer is the most commonly diagnosed cancer (excluding skin cancer) and 
the second leading cause of cancer deaths among women.2 Since early 2004, breast cancer 
incidence has been stable, while breast cancer mortality has been decreasing.3 But these changes 
have not been equal among all populations.3 
 
Elimination of health disparities is a goal of many federal agencies. For example, the US 
Department of Health and Human Services, the Agency for Healthcare Research and Quality, 
and the Centers for Disease Control and Prevention have developed action plans to reduce health 
disparities.4-7 Unequal incidence of advanced-stage breast cancer, receipt of high-quality 
treatment and breast cancer death rates have not changed much over time.5,8 Breast cancer 
incidence rates have been higher among white women, but mortality rates have been higher 
among black women. The annual average percentage change (AAPC) in incidence from 1999–
2013 varied by race; among white women there was a 0.8% decrease per year and a 0.4% 
increase per year among black women.9 Breast cancer mortality rates have fallen since the mid-
1990s to 2012 among both black and white women, but the rate of decline has been faster among 
white women (APC -1.9% versus -1.5%).10-12 Even though there have been great advancements 
in treatment options, racial inequalities in breast cancer survival in the United States still persist.  
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Evaluation of population-based survival trends can help to inform cancer control efforts by 
identifying opportunities for improvement in early detection, diagnosis, and treatment. 
Population-based survival is a key measure of the effectiveness of cancer management and 
treatment.13 Black women are more often diagnosed with regional or late stage disease and have 
higher death rates than white women, regardless of stage.14 In 2008, the CONCORD study 
reported 5-year population-based survival in 31 countries, including 22 registries in 16 US 
states.15 Five-year survival in North America was among the highest in the world at 84.0%, with 
large survival differences between white (84.7%) and black (70.9%) women in the United States, 
suggesting that black women may not have the same access to and quality of care as white 
women. The second cycle of the CONCORD program (CONDORD-2) examined survival from 
10 common cancers in 67 countries.16 CONCORD-2 is the largest study of population-based 
cancer survival trends to date, evaluating trends in 5-year survival for over 25 million individual 
patients diagnosed during the 15 years between 1995 and 2009. Age-standardized 5-year net 
survival from breast cancer increased in many countries world-wide. In the United States, it rose 
from 86.0% in 1995-99 to 88.6% in 2005-2009.  
 
Using the US data from CONCORD-2, we examined the distribution of breast cancer stage at 
diagnosis by race, state, and over time. We also analyzed survival trends by race, stage, and state.  
 
MATERIAL AND METHODS 
Data 
Breast cancer survival in the US by race and stage 
5 
 
We used data from 37 state cancer registries funded by either the CDC’s National Program of 
Cancer Registries, the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) program, or both. These registries participated in the CONCORD-2 study,17 covered 
approximately 80% of the US population. Registries consented to inclusion of their data in the 
more detailed analyses reported here. We analyzed individual tumor records for 1,372,377 
women (aged 15-99) who were diagnosed with breast cancer (International Classification of 
Diseases for Oncology 3rd edition - ICD-O-318 - C50.0-C50.6; C50.8-C50.9) during 2001-2009 
and followed up to December 31, 2009. We included primary invasive cancers of the breast, 
regardless of whether the woman had a previous cancer. If a woman was diagnosed with two or 
more cancers of the breast during 2001 through 2009, only the first was considered in the 
survival analyses. 
 
Patients were grouped by year of diagnosis into two calendar periods (2001-2003 and 2004-
2009) to reflect changes in the methods used by US registries to collect data on stage at 
diagnosis. From 2001, most registries coded stage directly from the source data to SEER 
Summary Stage 2000 (SS2000).19 From 2004, all registries began to derive SS2000 using the 
Collaborative Staging System.20  
Survival analyses 
We estimated net survival up to 5 years after diagnosis and 95% confidence intervals (CI) using 
the Pohar Perme estimator.21 We analyzed survival by race, stage at diagnosis, calendar period of 
diagnosis, and state.  Net survival is the probability of survival up to a given time since 
diagnosis, after controlling for other causes of death (background mortality). To control for the 
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wide differences in background mortality among participating states, we constructed life tables 
of all-cause mortality in the general population of each state from the number of deaths and the 
population, by single year of age, sex, calendar year and, where possible, by race (black, white), 
using a flexible Poisson model.22 The life tables have been published.23 
 
We estimated net survival using the cohort approach for patients diagnosed in 2001-2003, since 
all patients had been followed up for at least five years by December 31, 2009. We used the 
complete approach to estimate net survival for patients diagnosed during 2004-2009, because 5 
years of follow-up data were not available for all patients. Net survival was estimated for 5 age-
groups (15-44, 45-54, 55-64, 65-74, and 75-99 years). We obtained age-standardized survival 
estimates using the International Cancer Survival Standard (ICSS) weights.24 If two or more of 
the five age-specific estimates could not be obtained, we present only the pooled, unstandardized 
survival estimate for all ages combined. Trends, geographic variations, and differences in age-
standardized survival by race are presented graphically in bar-charts and funnel plots.25  
More details on data and methods are provided in an the accompanying article.26 
RESULTS 
There were 1,372,377 US women (85.1% white women and 10.4% black women) diagnosed 
with breast cancer in participating registries during 2001-2009. Overall there were no substantial 
changes in SEER Summary Stage distribution between 2001-2003 and 2004-2009 (Table 1). In 
2001-2003, most breast cancers were diagnosed at local stage (61%). Around 30% of the cancers 
were regional stage and less than 5% were distant stage.  The proportion of women with 
unknown stage was low at 7%. The distribution remained similar in 2004-2009, showing a slight 
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reduction of the percentage of cancers of unknown stage cancer.  The stage distribution varied 
slightly between states (Supplement Table 1). In both 2001-2003 and 2004-2009, a lower 
proportion of black women were diagnosed at local stage, and the proportion of distant stage was 
about 1.6 times that of white women.  
 
Survival decreased with time after diagnosis. Survival at 3 years was lower than at 1 year after 
diagnosis, and survival at 5 years was lower than at 3 years after diagnosis in both time periods 
(Table 2). In 2001-2003, breast cancer 5-year net survival for all races combined was high at 
88.2% and remained so at 88.6% during 2004-2009. Overall, the difference in 5-year survival 
between black women and white women was more than 10 percentage points in 2001-2003 and 
this disparity did not decrease over time. In 2004-2009, survival varied widely between states 
(range: 85.4%-92.4%) and it was systematically lower for black women (Supplement Table 2).  
 
Five-year net survival was high for women diagnosed with local stage cancer during 2001-2003 
at 98% and remained high for women diagnosed during 2004-2009 (Table 3).  In both time 
periods, the difference in survival between white women and black women was highest for 
regional (82.3% and 83.5% for white women vs. 69.9% and 71.8% for black women) and distant 
tumors (22.5% and 25.7% for white women vs. 15.2% and 17.1% for black women). This 
difference was noticed in all states and did not decrease over time (Supplement Table 3). For 
local stage, the racial disparity persisted but to a smaller extent (98.2% and 98.6% for white 
women vs. 92.8% and 94.3% for black women). 
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Figure 1 shows the 5-year age-standardized net survival by state. In 2001-2003, 5-year survival 
for breast cancer was very high at approximately 90%. Survival remained high in 2004-2009, 
with slight variation between states and regions.  There was 0.5% increase in net survival across 
the United States. The change in survival among states ranged from -2.9% to 3.6%. 
 
Figure 2 reports funnel plots of net survival for 2001-2003 and 2004-2009 to provide further 
insight into the variability of breast cancer survival in the United States by race and state. The 
plots show how much a particular survival estimate deviates from the pooled US value (the 
‘target’, represented in the plot by the horizontal line) given the precision of each estimate.24,25  
These plots show striking geographical and racial variation in survival. During 2001-2003 net 
survival was lower for black women in all states. Although survival for black women increased 
slightly during 2004-2009, survival remained lower for black women compared to white women 
in most states. In most states, survival for white women was above the pooled US estimate, while 
survival for all black women was below the pooled US estimate. 
 
DISCUSSION 
This study is the largest study on trends in population-based breast cancer survival in the United 
States. It is also unique in that the data are analyzed by race, stage at diagnosis, and state. This 
expands the US results from CONCORD-2, by providing detailed analysis of net survival by 
race and stage at diagnosis. Population-based survival is a key measure of the overall 
effectiveness of the health system in dealing with cancer and therefore is a useful measure for 
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evaluating access to and quality of care and appropriate treatment. These results can be used to 
plan future cancer control strategies. 
 
Overall, survival for breast cancer was strikingly high in 2001-2003 and remained high during 
2004-2009. There was wide variability in survival between states, with lower survival for black 
women than white women in all 37 states included in the analyses. Disappointingly, the more 
than 10% difference in survival between white and black women did not improve over time. 
More efforts need to be initiated to understand the reasons for this persistent racial disparity in 
breast cancer survival and to help black women in accessing early diagnosis and appropriate 
treatment.  
 
Black/white inequalities in survival suggest differences in access to care and differences in tumor 
morphology between the groups. With the same stage of disease, net survival is lower among 
black women. However, black/white differences in mammography rates by state are not 
consistent with stage of disease or survival. In fact, there are no significant state-specific 
differences between black and white women who report having had a mammogram within the 
past two years during the study periods.27  
 
Clinical perspective 
Having access to diagnostic studies and high quality treatment is important for improving breast 
cancer survival. Black women are more likely than white women to experience delays in 
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treatment and not receive appropriate treatment for breast cancer.28 Delays in care and 
inappropriate treatment can result in larger tumors and poorer outcomes. Timely follow-up of 
abnormal test results and receipt of treatment after diagnosis could improve outcomes of all 
women with breast cancer.29 Access to quality care is a key factor to reducing disparities in 
breast cancer survival.  
 
Breast cancer is a very heterogeneous disease. There are several different types of breast cancer 
with multiple sub-types based upon biomarkers such as estrogen receptor, progesterone receptor, 
and human epidermal growth factor receptor status. Differences in tumor morphology not only 
dictate treatment but also are prognostic. For example, triple negative breast cancer (breast 
cancer subtype that does not have estrogen and progesterone receptors or HER2 protein) is a 
more aggressive tumor with lower survival that is more often diagnosed among black 
women.30,31 There may be other tumor characteristics or underlying biologic differences between 
black and white women impacting tumor progression or therapy response that could be 
contributing to the observed survival differences by race. 
 
Research is continually identifying new tumor biomarkers that have potential for use in a clinical 
setting. As treatment becomes more individualized, not all options are always available to all 
patients. Therefore, as newer treatments improve survival, it may not improve survival among all 
women equally. If minority or low-income women do not have access to newer treatment 
options, survival improvements may not be as apparent among these groups in population-based 
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surveillance systems. This may be one reason we see that at the same stage of diagnosis, net 
survival is lower among black women than among whites.  
 
Cancer Control perspective 
In addition to addressing potential racial differences in the clinical care for breast cancer to 
reduce racial breast cancer survival disparities, there are several health behavior factors that can 
reduce risk for breast cancer.32-35 Modifying risk factors such as obesity, lack of physical 
activity, alcohol consumption, exposure to environmental toxins, and use of hormonal therapy 
can reduce a woman’s risk of getting breast cancer. Black women often have more co-morbid 
conditions which put them at greater risk for poorer survival outcomes.36 For women who may 
be at high risk for breast cancer due to family history or genetic reasons, they may need 
enhanced screening and risk reduction procedures such as taking antiestrogens or having 
prophylactic mastectomy. Minority and low-income women more often have limited access to 
these options37,38 which ultimately may put them at increased risk of dying from breast cancer.  
 
Once diagnosed with breast cancer, women need to be educated and empowered to take part in 
treatment decisions and to receive timely, guideline-concordant, and complete treatment. Women 
who have lack of trust in the health care system or who are characterized by cultural differences 
from their health care providers, may not get the needed treatment and supportive care.39 Studies 
that analyzed the availability of equal treatment among all patients found that patient have 
similar outcomes when they receive equal treatment.40-43 This suggests that the large and 
persistent survival deficit in black women during 2001-2009 may be attributable to receipt of less 
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effective treatment. Supportive care is also an area that needs more attention. Specifically, 
interventions to address geographical isolation, cultural differences, financial burden, and fear 
may be needed to improve access to quality care. These issues may be addressed along with 
clinical care.  
 
Strengths and Limitations 
This is the largest study comparing breast cancer survival by state and race using data from 
CONCORD-2 which includes high-quality data covering more than 80% of the US population.  
In addition, for women diagnosed with breast cancer, 98.9% of cases were morphologically   
verified, and the percentage of cases with unknown stage was low .44 All the participating  
registries were certified by the North American Association of Central Cancer Registries as 
having met data quality and completeness standards 
(http://www.naaccr.org/Certification/Criteria.aspx).   
 
This study had a few limitations. First, the follow-up procedures in the United States differed 
according to the federal funding source.45 All SEER registries are required to conduct follow-up 
of all cases to ascertain vital status. NPCR registries are only funded to ascertain deaths through 
linkage with the state vital records and the National Death Index. Second, the manner in which 
SEER Summary Stage 2000 data were collected and reported changed for all registries in 2004 
as described in the methods section. This resulted in the percentage of unknown stage cases 
decreasing when stage was derived rather than manually coded. Some state cancer registries 
assumed a case to be alive if the case was not included on state death certificate databases or on 
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the National Death Index. Next, the states in the Western Region (Mountain and Pacific 
Divisions) have too few black women to reliably assess racial differences and some states did not 
report stage data which could result in the data not being generalizable to the entire United 
States. Finally, vital status follow-up data was only available through December 31, 2009. 
Therefore, we did not have 5-year follow-up for each patient. 
 
Conclusion 
There is increasing awareness and effort to achieve health equity among racial, ethnic, 
geographic, socioeconomic, and other groups. With the persistent disparity in breast cancer 
survival between black women and white women, more national, local, and individual efforts are 
needed. This study provides accurate, useful information on incidence and survival of breast 
cancer patients in various US subpopulations and is supported through a nation-wide system of 
central cancer registries funded by CDC’s NPCR or NCI’s SEER program.45 
 
CDC and its partners are dedicated to identifying and addressing the factors that lead to health 
disparities among racial, ethnic, geographic, socioeconomic, and other groups so that barriers to 
health equity can be removed. CDC’s National Breast and Cervical Cancer Early Detection 
Program works with the states, tribes/tribal organizations, and territories to provide assistance to 
low-income women to ensure that they have access to appropriate breast and cervical cancer 
screening, diagnostic, and treatment services.45 The CDC’s Comprehensive Cancer Control 
Program works with states, tribes/tribal programs, and territories to develop cancer control plans 
that focus on prevention, screening, and survivorship issues.45 Working with partner 
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organizations such as the National African American Tobacco Prevention Network and the 
National Alliance for Hispanic Health, these programs target specific populations who are at risk 
of developing or dying from cancer.  
 
Eliminating or reducing disparities in breast cancer survival will require broad, coordinated 
population efforts at various federal, state, and local levels. The persistent black/white disparities 
in breast cancer survival reported here demonstrate that increased focus on individual, provider, 
community, organizational, and policy levels are warranted. Public health has an important 
opportunity to expand outreach to medically underserved women, provide education about breast 
cancer risk reduction, and increase awareness about post-treatment strategies to improve 
outcomes. Evidence-based interventions to further improve provider awareness, knowledge and 
practice need to also be identified. Finally, public health professionals can champion community-
level engagement and partnerships to leverage organizational infrastructure and provide evidence 
to inform organizational policies to ensure equal cancer care among all women and reduction in 
breast cancer survival disparities.  Focusing on education and informed decisions, cultural 
sensitivities, personalized care, and equal access to care are critical steps. 
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Tables and Figures  
Table 1. Breast cancer: number of cases for females (aged 15-99 years) diagnosed 2001-2003 
and 2004-2009 and distribution (%) by SEER Summary Stage 2000 at diagnosis, by race and 
calendar period of diagnosis. 
 
Table 2.  Breast cancer: age-standardized net survival (%) at 1-, 3- and 5-years for females (aged 
15-99 years) diagnosed 2001-2009, by race and calendar period of diagnosis. 
Table 3. Breast cancer: 5-year age-standardized net survival (%) for females (aged 15-99 years) 
diagnosed 2001-2003 and 2004-2009, by SEER Summary Stage at diagnosis, race, and calendar 
period of diagnosis. 
 
Figure 1. Breast cancer: 5-year age-standardized net survival (%) for adult females (aged 15-99 
years) diagnosed during 2001-2003 and 2004-2009, and absolute change (%): states grouped by 
US Census Region. 
Note:  Data from 37 statewide cancer registries (covering 80.6% of the population) are ranked 
within US Census Region by the survival estimate for 2004-2009. Dark colors denote states 
funded by CDC’s National Program of Cancer Registries (NPCR); pale colors denote states 
funded by NCI’s Surveillance, Epidemiology and End Results (SEER) Program; * denotes states 
funded by both federal surveillance programs.  Change (%) not plotted if a survival estimate was 
not available for one calendar period or one or more estimates was not age-standardized.  
 
Figure 2. Breast cancer: 5-year age-standardized net survival (%) for adult females (aged 15-99 
years), by state, race and calendar period of diagnosis.  
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Note: the pooled (US) survival estimate for each calendar period is shown by the horizontal 
(solid) line with corresponding 95.0% and 99.8% control limits (dotted lines). 
 
Supplement Table 1. Breast cancer: number of cases for females (15-99 years) diagnosed 2001-
2009 and distribution (%) by SEER Summary Stage 2000 at diagnosis, by race, calendar period 
of diagnosis, and US Census Region and States. 
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009.   
 
Supplement Table 2.  Breast cancer: age-standardized net survival (%) at 1-, 3- and 5-years for 
females (15-99 years) diagnosed 2001-2009, by race, calendar period of diagnosis, and US 
Census Region and States.  
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Unstandardized estimates are italicized.  
 
Supplement Table 3.  Breast cancer: 5-year age-standardized net survival (%) for females (15-99 
years) diagnosed 2001-2009, by SEER Summary Stage 2000 at diagnosis, race, calendar period 
of diagnosis and US Census Region and States. 
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program.  Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009. 
Unstandardized estimates are italicized.  
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Table 1.  Breast cancer: number of cases for females (aged 15-99 years) diagnosed 2001-2003 and 2004-2009 and distribution (%) by SEER 
Summary Stage 2000 at diagnosis, by race and calendar period of diagnosis. 
 2001-2003 2004-2009 
SS2000 
 
All races White Black All races White Black 
No. of patients 
 
446,106 385,888 42,401 926,271 782,220 100,611 
Local (%) 59.1 60.5 47.5 59.1 60.5 48.5 
Regional  (%) 29.8 29.1 35.3 30.2 29.6 35.2 
Distant (%) 4.4 4.2 6.8 5.2 4.9 7.8 
Unknown (%) 6.7 6.2 10.3 5.4 5.0 8.4 
 
 
Table 2.  Breast cancer: age-standardized net survival (%) at 1-, 3- and 5-years for females (aged 15-99 years) diagnosed 2001-2009, by race 
and calendar period of diagnosis. 
 2001-2003 2004-2009 
 
All races White Black All races White Black 
Years NS 
(%)  
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI 
1 96.5 96.4 - 96.6 96.8 96.7 - 96.9 92.6 92.2 - 93.0 96.7 96.7 - 96.8 97.0 97.0 - 97.1 93.6 93.3 - 93.8 
3 91.8 91.6 - 91.9 92.5 92.4 - 92.7 83.1 82.5 - 83.7 92.1 92.0 - 92.2 92.9 92.7 - 93.0 84.3 83.9 - 84.8 
5 88.2 88.0 - 88.3 89.1 88.9 - 89.3 76.9 76.2 - 77.6 88.6 88.4 - 88.8 89.6 89.4 - 89.8 78.4 77.7 - 79.1 
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Table 3.  Breast cancer: 5-year age-standardized net survival (%) for females (aged 15-99 years) diagnosed 2001-2003 and 2004-2009, by 
SEER Summary Stage at diagnosis, race, and calendar period of diagnosis. 
 2001-2003 2004-2009 
 All races White Black All races White Black 
SS2000 NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI 
All stages 88.2 88.0 - 88.3 89.1 88.9 - 89.3 76.9 76.2 - 77.6 88.6 88.4 - 88.8 89.6 89.4 - 89.8 78.4 77.7 - 79.1 
Local 98.0 97.8 - 98.2 98.2 98.0 - 98.4 92.8 91.9 - 93.7 98.3 98.1 - 98.6 98.6 98.3 - 98.8 94.3 93.4 - 95.2 
Regional 81.2 80.8 - 81.6 82.3 82.0 - 82.7 69.9 68.5 - 71.2 82.3 81.9 - 82.7 83.5 83.0 - 83.9 71.8 70.4 - 73.2 
Distant 21.5 20.9 - 22.2 22.5 21.7 - 23.2 15.2 13.6 - 16.9 24.5 23.7 - 25.2 25.7 24.9 - 26.6 17.1 15.4 - 18.8 
Unknown 72.5 71.8 - 73.2 73.1 72.4 - 73.9 65.9 63.8 - 67.9 72.6 71.9 - 73.4 73.2 72.4 - 74.1 68.3 66.3 - 70.4 
 
